BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. - Wikidata - wikimedia - TriplyDB

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.

http://www.wikidata.org/entity/Q37507410

about

Developing and evaluating polygenic risk prediction models for stratified disease prevention.Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.Breast cancer risks and risk prediction models.Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling.Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients.Gene-panel sequencing and the prediction of breast-cancer risk.iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management.Counsellee's experience of cancer genetic counselling with pedigrees that automatically incorporate genealogical and cancer database information.Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families.Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies.Non-invasive optical spectroscopic monitoring of breast development during puberty.Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.The evolution of cancer surgery and future perspectives.Molecular epidemiology, and possible real-world applications in breast cancer.Classification and Clinical Management of Variants of Uncertain Significance in High Penetrance Cancer Predisposition Genes.Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries.Performance of BRCA1/2 mutation prediction models in male breast cancer patients.Family History of Breast Cancer, Breast Density, and Breast Cancer Risk in a U.S. Breast Cancer Screening Population.Testing for Gene-Environment Interactions Using a Prospective Family Cohort Design: Body Mass Index in Early and Later Adulthood and Risk of Breast Cancer.Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci.A GPS-Based Methodology to Analyze Environment-Health Associations at the Trip Level: Case-Crossover Analyses of Built Environments and Walking.Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks.Breast cancer screening (BCS) chart: a basic and preliminary model for making screening mammography more productive and efficient.Dependence of cancer risk from environmental exposures on underlying genetic susceptibility: an illustration with polycyclic aromatic hydrocarbons and breast cancer.Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.pedigreejs: a web-based graphical pedigree editor.Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia.The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.Genetic testing in women with breast cancer: implications for treatment.Prediction of breast cancer risk based on flow-variant analysis of circulating peripheral blood B cells.Patient-Centered Care in Breast Cancer Genetic Clinics.Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability.

P2860

Q30251440-930B1903-C900-454C-A200-64BC9EF87945 Q34339960-055152C9-EE3E-4F16-8FDE-83A6766FBF18 Q35155449-AF240643-2F6E-4774-9BDC-2F1531C5ACA6 Q35399596-6692D33E-9BAB-4FE5-9C0F-05E6744446AB Q35736188-53D6BA3C-3904-4487-932C-0588276B5515 Q35848518-35A7F656-2D7D-435A-AA3F-9735E2303237 Q35886203-8CD62112-9475-4459-BEB0-E4F7BE6D31A1 Q35901598-09737452-BE3D-4192-9A95-B99A21D56BD3 Q36175072-DE851619-45BC-4CF9-8066-98917C38E199 Q36678510-60B280C8-7CE9-42D3-8B05-047649391C59 Q37124135-EEE72761-2CDD-487F-A0A3-19E45CDC7FAB Q37131918-1F68A79A-CCC9-4C79-9C79-CA27E9B6A7B2 Q37378034-92B8551E-943A-41CA-98B4-F18A2253C8AE Q37524981-8026FD58-D04A-4CE6-BC3B-9374EA7BBA83 Q37628084-DF340A8C-5280-49C7-B3AF-42A5ABE62D2A Q37710182-D00B8533-492E-45AC-BAD4-B07D8ACE74F1 Q37716586-2CA059FE-339D-4B9E-8C1E-0CD174CABE86 Q38266722-02111643-156E-4219-9119-8FC7ACA7EC6D Q38415320-1A1B7305-D428-48A3-A687-5DD4C6E9E91B Q38700025-9E9A2171-273D-4EB3-9BEA-275DAE56A27B Q38721663-BA57C5AF-D2B0-4FA6-AB6D-B688DCCEFCDA Q38739022-6C8C8290-1FC9-42F6-984D-842F121668AB Q38769347-D434400F-3EDE-46E4-8097-A27E7E37458D Q38842051-F4EBE239-E6D1-45A9-9D53-ED5DDE78FE81 Q39263736-3F398BEB-B632-4A18-9AA1-5499FC14AE1E Q39326953-C9144B8F-D3D8-4C10-AA51-144635192F1A Q39360191-1592B3CF-D65B-4B22-9CEA-BF01CFEFF4AD Q39437211-551587B3-EB22-49C1-A0F1-7DF7B74E296D Q39958494-37401DE2-C3BC-40DC-AA28-E70C15CEC4A6 Q40094101-81EC4335-F30C-486E-A593-998D636C42FD Q40201038-47224159-4511-49E1-B3A0-B583C26F4A5B Q40270211-F670C4F8-E2A7-458C-94FF-B036F9F33F98 Q40903518-C1534090-D0FB-4599-A428-1D6729A607C0 Q42695202-96EB5728-9790-44F5-A5F6-39B53A8C0E2C Q47586106-A613E6C6-E206-43EF-AF2B-4F543265AED4 Q47686082-03D6C84A-7624-4B4C-AF0D-69680BFF5037 Q47884776-037446F5-58DE-4FF6-A6EB-82C20A4EAF36 Q48115820-6ECFE800-1148-415B-A3C2-3F76A5B06D0D Q50033737-35E7D4B2-7A0C-4E94-8090-6BAF24E67930 Q51016187-9803EDC5-1721-4482-9B94-1F340A9DAE8F

P2860

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.

http://www.wikidata.org/entity/Q37507410

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

BOADICEA breast cancer risk pr ...... r pathology and web interface.

@en

BOADICEA breast cancer risk pr ...... r pathology and web interface.

@nl

type

label

BOADICEA breast cancer risk pr ...... r pathology and web interface.

@en

BOADICEA breast cancer risk pr ...... r pathology and web interface.

@nl

prefLabel

BOADICEA breast cancer risk pr ...... r pathology and web interface.

@en

BOADICEA breast cancer risk pr ...... r pathology and web interface.

@nl

P1433

Q37507410-E7E30164-73A3-4CD7-840F-32AA6A2D5F17

P1476

Q37507410-0BAA6990-3551-4033-AD9E-5A244848CE6C

P2093

Q37507410-42AC63DD-4662-4E27-8FBF-FF520103BC58

Q37507410-6A06C67B-FB34-4E5D-A5CB-26ECCCE52F31

Q37507410-9C5D3186-634E-4B8F-B389-20880148E5DB

Q37507410-E8BE08F2-2A89-426F-8B9C-5147E171E55F

Q37507410-EBE3CEB8-7B2E-489F-AF10-1F3AD79CB9B6

Q37507410-F94E8CF4-3F00-4742-AF48-4C30519F6CF4

P2860

Q37507410-017ECF68-6E19-4C90-A191-D52AE47AF9ED

Q37507410-17562665-9FCF-4557-A080-CC969BB89E73

Q37507410-2496DAA3-6B02-48EC-ACD3-5A92A02E4DAD

Q37507410-254321BA-4B8E-47CA-80BE-BF6009515B1B

Q37507410-25EFA3BB-EDE9-44A7-B728-0235684CDB19

Q37507410-265E4405-EF85-4ECB-BCC4-F8F8D2FBF7B7

Q37507410-283110DB-2BDA-44FA-973D-D70B99BB92B9

Q37507410-28795924-94C2-4A71-8DCE-6DB7EFD4AEB9

Q37507410-297799EC-83CE-443B-B8F3-455EAE7728B3

Q37507410-2A9CA5AD-1F48-43CA-BC31-2E6376659EAE

P2888

Q37507410-00411AE4-BA6F-4A2D-A277-2F844CE701BD

P304

Q37507410-B0013D32-1D64-429A-A691-8C867E3A3E07

P31

Q37507410-BA1F87CC-94E3-41A6-96EB-5E2631173A63

P356

Q37507410-C80D41C7-12FA-438F-A91D-75E2D87F0B6B

P407

Q37507410-704FCC01-DCAA-450A-BF93-89A5F2A21980

P433

Q37507410-89A08563-BA95-4D86-A5A8-A3BE695AF584

P478

Q37507410-4C711301-2655-440D-BF2D-72C34FA933C1

P50

Q37507410-46A6F182-0D03-4C3D-B6A8-2A412543D92D

Q37507410-5FF09D02-BEB4-42DA-A42D-5F655BC29212

P577

Q37507410-E03B5EF9-7977-4451-AAE1-B316D17A3B94

P5875

Q37507410-5EAA6ADB-3D2D-4B46-9F5C-0C3EFAA903C0

P6179

Q37507410-2043707E-8792-4CDD-9712-82F9D019A38D

P698

Q37507410-10EA22ED-5A0B-4D22-9DD2-4208A487F0AC

P921

Q37507410-5ee0ba64-77f2-48c5-a41a-42abf5eda52e

P932

Q37507410-6C52E0A1-EE64-4CE1-9B2B-887D1FE3CDBF

P356

P1433

British Journal of Cancer

P1476

BOADICEA breast cancer risk pr ...... r pathology and web interface.

@en

P2093

A J Lee

http://www.w3.org/2001/XMLSchema#string

A P Cunningham

http://www.w3.org/2001/XMLSchema#string

Breast Cancer Association Consortium

http://www.w3.org/2001/XMLSchema#string

Consortium of Investigators of Modifiers of BRCA1/2

http://www.w3.org/2001/XMLSchema#string

K B Kuchenbaecker

http://www.w3.org/2001/XMLSchema#string

N Mavaddat

http://www.w3.org/2001/XMLSchema#string

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene

Genome-wide association studies identify four ER negative-specific breast cancer risk loci

Genome-wide association study identifies novel breast cancer susceptibility loci

Global cancer statistics, 2002

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations

Large-scale genotyping identifies 41 new loci associated with breast cancer risk.

Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

Incorporating tumour pathology information into breast cancer risk prediction algorithms.

P2888

P304

535-545

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2013.730

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Douglas F. Easton

Antonis C Antoniou

P577

2013-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259352461

http://www.w3.org/2001/XMLSchema#string

P6179

1032030618

http://www.w3.org/2001/XMLSchema#string

P698

24346285

http://www.w3.org/2001/XMLSchema#string

P921

P932

3899766

http://www.w3.org/2001/XMLSchema#string